MedTrace Logo

Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants

NCT04962022 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-07-13

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of PF-07321332/ritonavir in healthy participants.

Conditions

  • Healthy Participant

Interventions

DRUG

PF-07321332/ritonavir

Administered orally every 12 hours for days for a total of 5 doses from Day 1 through Day 3

DRUG

Itraconazole

Administered orally once daily for 8 days from Days 1 through 8

DRUG

PF-07321332/ritonavir

Administered orally BID for 3 day for a total on 5 doses starting on Day 4 through Day 6

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-20
Primary Completion
2021-09-30
Completion
2021-09-30
FDA Drug
Yes

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04962022 on ClinicalTrials.gov